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ABSTRACT 
Objective: This study was intended to investigate the potential of the colon specificity approach comprising of use of pH-sensitive and time-
dependent polymers in combination for precise colonic release of Mesalamine or 5-Aminosalicylic acid (5-ASA). 
Methods: The extrusion and spheronization method, preferably employed in industry for allowing high dose capacity to formulate, was used to 
prepare drug pellets. The Wurster coating technique used for aqueous coatings of Eudragit NE 40D as an inner coat and Eudragit FS30D as outer 
coat. The changing pH media used for in vitro release study of optimization batches for both the coating levels. A scanning electron microscope 
(SEM) was used to evaluate coating thickness and surface morphology. 
Results: The pharmacokinetic parameters of formulation evaluated by in vivo study in rabbits revealed that the uncoated formulation released the 
drug too early in the gastrointestinal tract (GIT) with a mean Cmax of 1205.28±0.37 µg/ml at 2 h after administration, whereas desired lag time was 
achieved in case of coated pellets exhibiting mean Cmax 465.94±0.21 µg/ml and tmax
Conclusion: The in vitro and in vivo release study divulge the reliability of approach involving the use of pH sensitivity and time dependency of 
polymer for drug release in a single formulation for the treatment of colonic diseases. Hence, the present study provides constructive results for 
colon targeting of 5-ASA pellets with industrially feasible processes. 
 of 8 h. 
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Recently, the occurrence of colon related diseases has increased greatly 
all over the world [1]. Mesalamine or 5-Aminosalicylic acid (5-ASA) is 
being more preferably used for the treatment of several colonic diseases 
such as IBD (inflammatory bowel disease), CD (Crohn’s disease) and 
ulcerative colitis [2]. All these diseases, if not treated in their early stages, 
may lead to colorectal carcinoma [3]. Many attempts have been made in 
the last decade for developing the effective formulation to release the 5-
ASA precisely in the colon without being released in other parts of the 
gastrointestinal tract (GIT) to avoid the premature absorption and loss of 
drug [4]. Prier literature projected a range of approaches either of 
colonic microflora degradable or use of pH or time-dependent polymers 
in matrix tablets. Very few of these attempts were able to make a 
correlation between in vitro-in vivo release of this molecule due to its 
drastic biovariavbility. Use of the solely pH-dependent approach for 
colon targeting has limitation as pH is highly-variable physiological 
parameter in IBD patients [5]. 5-ASA acts as an anti-inflammatory agent 
through inhibition of cyclooxygenase and by decreasing prostaglandin 
production and blocking the production of interleukin-1 (IL-1) and 
tumor necrosis factor-a (TNF-a) [6-7]. Several chronic serious diseases 
might be capable of being treated more effectively if drugs were targeted 
on the site of action with an appropriate release pattern [8]. Targeted 
delivery of the 5-ASA using multiparticulate system can be one of the 
more hopeful approaches that could enhance its efficacy with reduced 
associated side effects [9]. 
However, high biovariability and high dose limits the clinical 
application of 5-ASA. Hence, there is a pressing need to develop colon-
specific oral solid dosage form. In this framework, pellets offer 
advantages such as predictable gastric transit time, minimum local 
irritation, enhanced bioavailability, reduced dose dumping and readily 
coatable which render them suitable for controlled drug delivery [10-
14]. Prolonged residence time, specific pH level and microbial 
environment of colon represent the key elements for colon targeting 
[15]. However, the limitation is the pre-colonic drug release which can 
be circumvented by employing either prodrug, time-dependent and/or 
pH-sensitive approach [16]. A prodrug approach involving conjugation 
of drugs with biodegradable polymers requires toxicological data and 
hence limits its application [17]. The Famotidine time-controlled 
release pellets were developed by Zhang et al. using time-dependent 
polymer coating of Eudragit RS100 to protect drug release at upper 
GIT and incorporate required lag time [18, 19]. However, variation in 
gastric emptying time and intestinal transit time and need of 
advancement in manufacturing restricts the use of this approach [20]. 
One more approach exploits the drastic pH variation across the GIT, 
such as 1.2 in the stomach, 6.5 in the small intestine and 7.2 in the 
colon, and hence imply significance to deliver drug to the specific site 
using pH-sensitive polymer [21-23]. Polymers that mainly dissolve at 
pH above 6.8 can be employed for colon targeting e. g., polyvinyl 
acetate phthalate, cellulose acetate phthalate and copolymers of acrylic 
and methacrylic acid (Eudragit FS 30D, S100 and L100) [24, 25]. 
However, pH in GIT may be altered depending upon the disease 
condition, diet, age, sex, etc. Moreover, small difference in pH between 
the small intestine and the colon makes it alone as a less reliable 
approach [26]. Kadam et al. have reported theophylline loaded pellets 
using the combination of time-dependent and pH-sensitive polymers 
as Eudragit RL100 and Eudragit S100, respectively to develop more 
reliable colon targeted system [27]. 
Hence, the objective of this study was to develop a more promising, 
time-dependent and pH-sensitive combination-based 5-ASA loaded 
pellets for colon targeting. Eudragit FS30D (with superior site 
specificity than commonly employed Eudragit S100) was used for 
outer coating [28], whereas Eudragit NE40D as an inner coating 
material produced sustain release characteristics. The Wurster coating 
process was used due to its industrial acceptance, technological 
advancements, predictable and cost-effective scaling up capability and 
higher drying capacity for aqueous coating. The pharmacokinetic 
parameters were evaluated on optimized composition. 
MATERIALS AND METHODS 
Materials 
5-aminosalicylic acid was procured from Sigma Aldrich Co. IPCA 
Health Products Ltd. (Mumbai, India) provided Avicel PH 101, 
Hypromellose and polyvinylpyrrolidone (PVPK30). Eudragits 
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NE40D, Plasacryl T20, and Eudragit FS30D were received as gift 
samples from Evonik Röhm GmbH (Darmstadt, Germany). Other 
excipients used to prepare pellets and coating dispersion were of 
standard pharmaceutical grade and all chemical reagents of 
analytical grade. Other materials namely, isopropyl alcohol (IPA), 
Talc, Triethyl citrate (TEC) and Glyceryl monostearate (GMS) was 
purchased from SD Fine-Chem. Ltd., (Mumbai, India). 
Methods 
Preparation and optimization of drug-loaded pellets 
Pellets were prepared by extrusion-spheronization technique. 
Extruder-20 (Anish Pharma) with a sieve size of 1 mm with use 
of speed 45 rpm and Spheronizer-250 (Anish Pharma) with 
plate size of 4.2 mm were used. The composition of pellets is 
listed in table 1. Drugs and all the excipients were sieved 
through a 400 µm screen and mixed thoroughly. Binder 
solution was prepared by dissolving 3 % w/w 
polyvinylpyrrolidone (PVPK30) in purified water under 
continuous stirring. PVP K30 solution was uniformly kneaded 
with above mixture to obtain a damp mass of required 
plasticity. The damp mass was passed through extruder and 
then extrudates were immediately spheronized to obtain 
pellets. Drug loaded pellets were dried in an oven at 40 °C for 
24 h. 
Friability 
Friability was tested with 3 g of uncoated pellets placed in friabilator 
having 12 steel balls (0.445 g each) and tumbled at 25 rpm speed for 
4 min. 
Drug content 
The drug content of Mesalamine was determined (sample size of 100 
mg pellets) by using UV-Visible 2501 PC spectrophotometer 
(Shimadzu Co., Kyoto, Japan) at 302 nm. 
Preparation of coating dispersion and coating of pellets 
The new and innovative coating system additive, Plasacryl T20, 
was used during the preparation of Eudragit FS30D aqueous 
dispersion.  
The dispersion of TEC and Plasacryl T20 (ready to add system 
is 20 % emulsion consisting Polysorbate-80 as a surfactant, 
triethyl citrate (TEC) as a plasticizer and glyceryl 
monostearate (GMS) as an antitacking agent) in water was 
added to polymer dispersion under stirring and then 
homogenized for 10 min. The resultant dispersion was passed 
through 0.5 mm sieve. The composition of inner coating and 
outer coating dispersion is shown in table 2. 
 
Table 1: Composition of 5-ASA pellets 
Ingredients Quantity (g) 
5-ASA 90.00 
Avicel PH101 7.00 
PVP K30 solution (5% w/w) 3.00 (dry weight) 
Purified water (to maintain moisture level) q. s. 
The pelletization process was optimized by different spheronization speed and spheronization time to achieve uniform spherical pellets with 
sufficient hardness to avoid friability during subsequent processing. 
 
Table 2: Composition of coating dispersions 
Ingredients Eudragit NE40D (inner coating) Eudragit FS30D (outer coating) 
TEC (with respect to dry polymer) - 5 % 
GMS (with respect to dry polymer) 5 % - 
Plasacryl T20 (with respect to dry polymer) - 10 % 
Polysorbate-80 (with respect to dry GMS) 40 % - 
Total solid content of spray suspension 20-25 % 20-25 % 
Prepared coating dispersion was used for the coating of pellets using FBP (Model GPCG 1.1, Glatt). The process parameters related to FBP were 
optimized from the preliminary trials. 
 
Table 3: Optimized FBP parameters for the coating process 
Parameters Optimized values 
Spray type Bottom spray 
Bag type Finger bag 
Inlet temperature ( °C) 35 
Product temperature ( °C) 25 
Blower speed (Hz) 35 
Pump speed (rpm) 3 
Atomization pressure (bar) 1.2 
Nozzle diameter (mm) 1 
 
Table 4: Independent and dependent variables and the levels for coating 
Levels  Factors (Independent variables) Response (dependent variables) 
Inner coating level (XC1 Outer coating level (X) C2 Y) YC1 YC2 C3 
−1 8 % 8 % t t10% t50% 90% 
0 12 % 12 % 
+1 16 % 16 % 
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Table 5: Experimental design for coating 
Formulation code XC1 X (%)  C2 (%)  
F1 8 8 
F2 8 12 
F3 8 16 
F4 12 8 
F5 12 12 
F6 12 16 
F7 16 8 
F8 16 12 
F9 16 16 
 
Optimization of the coating process 
300 g of 5-ASA loaded pellets were coated using FBP. In-process 
sampling was done at regular intervals for observing coating 
morphology. At the end of coating, pellets were dried for 5 min by 
increasing temperature to 40 °C. Optimized coating parameters are 
enlisted in table 3. 
Optimization of coating levels 
Selection of inner coating level was necessary to achieve control 
drug release at the specific site of action and it is also important to 
optimize outer coating with Eudragit FS 30D for targeting the 
complete drug release in colonic site. The impact of inner and outer 
coating levels i.e. 8 %, 12 % and 16 % w/w (based on drug release 
profile of preliminary batches) on the drug release at given time 
period (t10%, t50% and t90%
Thermal analysis 
) was studied. Variables and their levels 
along with experimental design are described in table 4 and 5. 
DSC (Differential Scanning Calorimetry: Mettler Toledo DSC 822e) 
was performed to measure the amount of heat energy absorbed or 
released by a sample, as it is heated, cooled or held at a constant 
temperature. About 10 mg of the sample was placed in DSC 
aluminum pans of 40 μl and it is sealed. An empty sealed pan is used 
as reference. Sample was run in the required temp range in inert 
atmosphere at a gas flow of 80 ml/min. 
Powder X-ray diffraction study 
The sample was smeared over low background sample holder 
(amorphous silica holder) and fixed on the sample stage in 
goniometer. The instrument (Bruker Model D8 Advance) is set with 
B-B geometry. The current and voltage is set to 40 mV and 35 mA 
and data has been collected. 
Scanning electron microscopy (SEM) 
The coated pellets were evaluated for their surface morphology, 
shape, size and coating thickness. The sample was smeared on a 
small piece of adhesive carbon tape which is fixed on a brass stub. 
The sample, then subjected to gold coating using the sputtering unit 
(model: JFC1600) for 10 s at 10 mA of current. The gold coated 
sample placed in the chamber of SEM (Jeol, JSM 6390LA) and 
secondary electron/Back Scattered electron images are recorded. 
In vitro drug release study 
The changing pH media for delayed-release dosage form was used 
for studying the drug release from developed pellets. The dissolution 
test was conducted using USP type 1 apparatus (100 rpm, 37±0.5 °C, 
900 ml). Initial drug release studies were conducted in 0.1N HCl (pH 
1.2) for 2 h, subsequently in pH 7.4 (phosphate buffer) for 3 h and in 
pH 6.8 (phosphate buffer) till end of the test. 5 ml of aliquots were 
withdrawn at regular time intervals and replaced with fresh 
dissolution medium. The concentration of drug released was 
analyzed using UV spectrophotometer at wavelength of 301, 330 and 
334 nm for pH 1.2, pH 7.4 and pH 6.8, respectively. All the 
measurements were performed in triplicate [29]. 
Statistical analysis 
The statistical analysis was done using one-way ANOVA with the 
assistance of Graph Pad Instat software and P<0.05 was considered 
as a limit to indicate the statistical significance. 
In vivo study 
For effective colon targeted drug delivery system, the drug must be 
targeted to the mucosa of the terminal ileum and colon for localized 
release. The release of drug in the stomach and upper small intestine 
is undesirable as this will lead to premature absorption and 
consequent drug wastage as well as possible systemic side effects. It 
is very important to correlate the in vitro performance of colon-
specific formulation with in vivo studies for ascertaining site-
specificity due to the varied conditions in GIT of the formulations 
targeted to the ileo-cecal region for its site-specificity. Along with X-
ray imaging study, pharmacokinetic study gives the reliability on 
colon specificity. 
The animal experimental protocols were approved by the 
Institutional Ethical Committee for Care and Use of Laboratory 
Animal and they were handled according to the code of ethics in 
research, training, and testing of the drugs. The animals were 
sourced from the animal house of the Institute of Pharmaceutical 
Education and Research (IPER) Borgaon (Meghe), Wardha, India. 
The ethics committee approval number is: IPER/IAEC/2015-16/06. 
A two-way randomized crossover study was planned with the use of 
six white New Zealand rabbits, approximately 2 kg. Rabbits were 
kept on a standard diet and housed in separate standard cage racks 
with controlled humidity and temperature. For the study, rabbits 
were randomly divided into two groups and administered the two 
different pellet formulations. On the first day of the study, the 
uncoated formulation was given to group I, while group II was 
received the coated pellets, and vice-versa on the second part of the 
study. Fifteen days of washout period was allowed between 
administrations. Rabbits were fasted for 12 h before the study and 
throughout the study but had free access to water. Pellet 
formulations (coated or uncoated) containing 50 mg/kg of 5-ASA 
were filled into hard gelatin capsules (size 4) and administered 
orally to rabbits using a cannula. To facilitate the ingestion of the 
capsule, 5 ml of water to be given to rabbits through a syringe after 
administration of the capsules. Blood samples (700–800 µl) was 
collected through a catheter inserted into the marginal vein of the 
ear of the rabbits, at pre-determined times (0, 1, 2, 3, 4, 6, 8, 12 and 
24 h) and rapidly transferred into 1 ml blood collection tubes 
containing lithium–heparin. The plasma obtained after 
centrifugation of the blood samples at 13 800 rev/min for 15 min 
and kept at-80 °C until analysis [30]. 
Pharmacokinetics analysis 
Plasma concentration of 5-ASA concentration in the plasma (µg/ml) 
as a function of the time of administration (in h) was plotted for both 
uncoated and coated pellets formulations. The maximum 5-ASA 
concentration in the plasma (Cmax) is the arithmetic mean of values 
for the six rabbits in the two days of the study whereas the 
corresponding time (tmax) was read directly from the graph. The area 
under the 5-ASA plasma concentration-time curve (AUC0-24h
Stability study 
) was 
calculated using non-compartmental analysis (PK Solver 2.0). 
The stability study initiated by charging the sample in accelerated 
(40 °C and 75 % RH) for 3 mo and control sample at (25 °C and 60 % 
RH) and at room temperature. The sample at accelerated condition 
was removed at 1, 2 and 3 mo intervals and analyzed for drug 
content and release profile. 
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RESULTS AND DISCUSSION 
5-ASA pellets coated with a pH-sensitive polymer may have great 
implications to overcome the inherent problems of drug mainly 
biovariability concern as well as to target the specifically to colonic 
cells. Since pellets are transported rapidly from the upper GI tract, 
premature drug release from coated pellets is often restrained and 
certain areas of pathological interest in the lower GI tract can thus 
effectively be targeted. The better distribution of pellets at target 
site could potentially minimize the requirement of drug dosage and 
associated side effects as well. 
5-ASA is a high dose molecule and hence the extrusion-
spheronization process was selected considering the scalability and 
industrially acceptable approach for pelletization. Preparation of 
drug-loaded pellets through the multiple-step process of extrusion-
spheronization usually yields uniform and small-sized pellets with 
the advantage of incorporating efficiently higher levels of drug than 
other drug loading techniques. The pellets produced possess size 
ranging between 0.5 and 2.0 mm and have high density. Moreover, 
the technique can be industrially adopted owing to its simplicity, 
rapidity and reproducibility [31-33]. 
Extrusion-spheronization is also known to produce spherical pellets that 
bestow desirable attributes including uniformity in size distribution, 
good flow, low friability and ease of coating [31, 33] However, sphericity 
of the pellets is often influenced by many process variables, noticeably, 
the spheronization speed and the spheronization time. Hence, the 
spheronization process was optimized with respect to these variables 
and, expectedly, the chosen variables showed dominating authority on 
the spherical nature of the resultant pellets. With an increase in 
spheronization time and spheronization speed, pellets with very good 
roundness were observed. The selection of excipients was based on the 
results of preliminary trials. Avicel PH101 was used as a diluent, which 
also is known to aid the spheronization process and PVP K30 solution as 
a binder. The resultant pellets were evaluated for their physical 
characteristics which are discussed in the following section. 
Characterization of pellets 
Flow property is largely dependent on the particle size, shape and 
density, amongst many other factors. Improvement in flow 
properties can be brought about by increasing the particle size 
and/or by producing spherical particles. Also, the amount of 
moisture associated with the drug and excipients during the 
pelletization process has an influence on the flowability and hence 
proper drying of pellets was ascertained. The screen diameter 
determines the pellet size whereas pellet shape is determined by the 
variables in the spheronization process (importantly, spheronization 
speed and time) [34]. Initial particle break-up of the extrudates is 
triggered by the speedy motion of the spheronizer while the 
collision frequencies and duration of the collision of the particles 
determine the roundness/sphericity of pellets. Sphericity is a key 
factor for the coating and flow behavior of the pellets. 
Friability test reveals the mechanical strength of the pellets required 
for further processing, including film coating. Certain hardness of 
pellets is a prerequisite for the coating process, especially in Wurster 
coating, to withstand the collisions in between particle-particle and 
particle with the walls of the instrument. Friability of pellets tested 
with steel balls was below 0.1 %, signifying suitability of the pellets 
in Wurster coating process. Drug content or content uniformity 
shows that the drug is uniformly distributed in formulation, which 
ensures the safety, efficacy and quality of product. 
Coating of pellets and characterization of coated pellets 
With concern towards environmental protection, use of aqueous-based 
solution/dispersion is recommendable for coating purposes. Eudragit 
NE40D is a neutral polymer consisting of an aqueous dispersion of poly 
(ethyl acrylate, methyl methacrylate) in 2:1 proportion and is non-toxic 
and does not produce any marked biological action. Its minimum film-
forming temperature (MFT) is ∼5 °C and allows formation of a water-
insoluble, soft and flexible film spontaneously without employment 
of plasticizer [35-37]. While Eudragit FS30D is an aqueous 
dispersion of an anionic and random copolymer based on methyl 
acrylate, methyl methacrylate and methacrylic acid (7:3:1) with MFT 
of ∼14 °C [28].  
The coating levels were optimized using the optimized batch of 
uncoated pellets to achieve inner and outer coat weight gain of 8 %, 
12 % and 16 % (w/w) for respective Eudragit grades. The coating 
efficiency was determined which is expressed as the ratio of actual 
weight gained to the theoretical weight gain expected to be obtained 
after coating with respective coating levels. All the factorial batches 
(F1-F9) showed optimum coating efficiency for Eudragit NE40D as 
well as for Eudragit FS30D ranging from 98.11 % to 99.87 %. 
DSC thermogram of the pure drug 5-ASA (fig. 1a) showed a 
characteristic exothermic peak at 280.20 °C, which was within the 
range of the melting point of the drug. Formulation composition 
containing 5-ASA and excipients exhibited a similar exothermic peak 
at 271.61 °C (fig. 1b). The observed melting point range was found to 
be in close proximity to the values reported. This study confirmed 
that there was no interaction between the drug and polymers used. 
The 2θ values from the powder XRD studies for 5-ASA were found to 
be 14.991ᵒ and 26.922ᵒ as per the represented powder XRD curves 
in the (fig. 2a) and a sharp intense peak indicated the crystallinity of 
the drug. The 2θ value of formulation composition containing 5-ASA 
and excipients were found to be 15.030° and 26.965ᵒ (fig. 2b) 
indicating its crystalline nature. The 2θ value confirmed that the 
drug and the polymer existed in the crystalline state without any 
interaction and polymorphic change. 
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Fig. 2: XRD curves of pure drug 5-ASA (fig. 2a) and 5-ASA and excipients (fig. 2b) 
 
SEM is one of the established and widely used techniques for the 
analysis of shape and size of different drug delivery systems 
(Danaeiet al. 2018). SEM photographs revealed that the rough 
surface of core pellets (fig. 3a,) was almost getting covered after 
coating with improved surface texture and smoothness (fig. 3b and 
fig. 3c). The deformities like cracks and pores generally get formed 
during the pelletization process and are unavoidable. The coated 
pellets were larger in size as compared to uncoated pellets with 
about 1.0-1.22 mm of diameters. The average coating thickness 
estimated from SEM analysis was 73.91±2.0 µm (fig. 3d, 3e, and 3f). 
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Fig. 3: Representative scanning electron micrographs depicting the overall appearance and surface morphology of core pellets (Fig.: 3a) 
and size and coating thickness of coated pellets (Fig.: 3b, 3c, 3d, 3e and 3f) 
 
In vitro drug release study 
For a colon targeted drug delivery system to be successful, its 
release pattern should have specific characteristics so that in 
stomach pH it should show minimum drug release (for the first 2 h) 
and should show maximum release in the colonic pH afterward. 
Since gastric transit time for similar drug delivery formulations is 2 
h and for small intestine is 3 h [38], the drug release was designed to 
change the pH of the media at certain time intervals accordingly.  
The governing factors for targeted colonic drug release include pH and 
residence time at different parts of GI tract. The peculiar pH-sensitivity 
of Eudragit FS30D is responsible for protection to the pellets in gastric 
environment, whereas pH independent permeability of water-
insoluble film of Eudragit NE40D increases with time, and so provides 
an appropriate choice for the development of oral sustained release 
dosage forms. The pH in the GIT varies greatly depending up on-site 
and state of fasting or fed (in stomach, Fasted: 1.5-3 Fed: 2-5) in small 
intestine (Duodenum, Fasted: ≈6.1 and Fed: ≈5.4, Jejunum Fasted: 6-7, 
Ileum: ≈7-8). In large intestine also it varies significantly (Cecum: 6.4, 
Ascending colon 5.7, Transverse colon 6.6, Descending colon and in 
rectum 7.0). Hence, in combination of pH and time-dependent systems, 
if in case pH-sensitive polymer (Eudragit FS30D) could not achieve 
release in colon due to pH variability, then time dependant polymer 
(Eudragit NE40D) contribute for controlling the release. As the pH of 
colon changes drastically in colonic diseases, and to simulate the pH 
conditions of GIT changing pH media method was employed for 
dissolution studies. 
Fig. 4 shows 5-ASA release profiles in simulated gastric fluid (SGF, 
0.1 N HCl, pH 1.2) for 2 h and in pH 7.4 (phosphate buffer) for 3 h 
and pH 6.8 for further up to 24 h. Pellets coated with Eudragit 
NE40D at 8 % coating level (F1, F2 and F3) showed drug release 
only up to 9 h, 10 h and 12 h, respectively. The increase in release 
time from F1 to F3 batches is attributed to an increase in outer 
coating level of Eudragit FS30D (table 5). Batch F4 with 12 % coating 
of Eudragit NE40D could sustain drug release up to 18 h. However, 
for efficient colon targeting, minimum drug release in initial 2 h and 
almost complete release up to 24 h is desirable [39] (Dukic-Ott et al., 
2008). Hence, results indicated inappropriateness of coating levels 
in F1-F4 batches. Batches F5 and F6 showed 5-ASA release more 
than 90 % in 24 h while batches F7-F9 could not completely release 
the drug within 24 h. The higher level of Eudragit NE40D (16 %) in 
batches F7, F8 and F9 were responsible for retardation of drug 
release. Accordingly, the foci for getting optimum coating levels 
were centered on F5 and F6 batches which showed 98.42±1.23 % 
and 91.88±0.91 % of 5-ASA release in 24 h, respectively. Another 
important aspect for colonic drug delivery is minimal drug release in 
the stomach, and both the batches (F5 and F6) offered less than 5 % 
of 5-ASA release in 2 h, demonstrating the gastroresistancy of 
Eudragit FS30D at 12 % and 16 % coating levels. Nevertheless, batch 
F5 is proposed superior over F6 (both with 12 % Eudragit NE40D 
level) since not only did batch F5 showed nearly complete drug 
release in 24 h along with comparable release in initial 2 h as F6, but 
also the cost of the polymer (that can have a significant role for large 
scale production of pellets) can be considered as an important 
selection criterion. Additionally, batch F5 showed only 27.85±0.41 % 
drug release in 6 h, which is the time required for pellets to reach 
colon, and hence precolonic release was minimized together with 
maximum release coinciding with colonic residence [27]. 
  
 
Fig. 4: In vitro percent cumulative drug release graph of formulations F1 to F9 containing 5-ASA in pH 1.2 (2 h), in pH 7.4 (2-5 h) and in pH 
6.8 (5-24 h) maintained at 37±0.5 °C (mean±SD, n = 3) 
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The rate of drug release was decreased with an increase in the inner 
coating level as Eudragit NE40D is water-insoluble and diffusion-release 
polymer over the entire pH range. It was also realized that higher coating 
level of Eudragit FS30D created larger lag time compared to the lower 
coating levels. Accordingly, the optimum formulation was selected based 
on the feasibility and cost-effectiveness of manufacturing, and lag time of 
6-8 h (resembling the time when drug formulations have adequately 
been localized in the colon). 
In vivo study 
5-Aminosalicylic acid plasma levels 
5-ASA plasma concentrations (µg/ml) obtained after oral 
administration of uncoated pellets and coated pellets, post-
administration a dose shown in fig 5. Maximum peak plasma 
concentrations of 5-ASA were reached faster after oral 
administration of the uncoated formulation (mean Cmax of 
1205.28±0.37 µg/ml at 2 h after administration) and in case of 
coated formulation (mean Cmax 465.94±0.21 µg/ml and tmax of 8 h). 
The mean AUC0-24h
The drug was released from the uncoated pellets without any delay 
i.e. showed high plasma concentrations in just 2 h, whereas for the 
coated formulation, drug release was much lower and only increased 
after 8 h of administration. The difference in vivo behavior of both 
formulations suggests the efficiency of coating.  
 values obtained with the uncoated and coated 
formulations were 4325.58 and 5870.21 µg h/ml, respectively. 
Mouth to ileum transit times of cell wall material in rabbits was 
found to vary between 6 to 7.9 h [40]. In another study, transit of 
food in the form of individual particles through the stomach of 
rabbits was found to be in the range of 3–6 h, and shorter transit 
times were found in the small intestine (10–20 min in the jejunum 
and 30–60 min in the ileum) [41]. Following administration of the 
uncoated formulation and based on the previously documented 
transit times, 5-ASA release and absorption should have occurred 
mainly in the rabbit’s stomach and proximal small intestine. On the 
other hand, following administration of the coated formulation, 5-
ASA release and subsequent absorption were more significant upon 
entering the rabbit’s caecum. In the literature, the upper intestines 
are reported to be the preferential site within the gastrointestinal 
tract for 5-ASA absorption. For example, in humans, 5-ASA 
absorption through the duodenum was reported to be 5-fold higher 
than in the ileum [42]. Therefore, the finding that the plasma level of 
5-ASA after administration of the coated formulation remained low 
for 8 h (i.e. during the transit of the pellets through the stomach and 
small intestine) indicates that the coating was able to prevent drug 
release at these sites. 
 
 
Fig. 5: 5-Aminosalicylic acid Plasma concentration vs Time curve obtained for uncoated and coated pellets (mean±SD) 
 
CONCLUSION 
Overall, the study proposes a method for the preparation of 5-ASA 
loaded pellets for colon-specific delivery with prominent in vitro-in vivo 
correlation and with scalable-industrially acceptable manufacturing 
process. Extrusion-spheronization was found to be an efficient 
pelletization method for achieving sphericity and strength. Additionally, 
this fast and efficient technique offers high drug loading capacity. The 
combination of pH-sensitive and time-dependent polymers in 
development of pellets provides assurance of effective colon targeting of 
5-ASA. The aqueous coating and Wurster process further strengthen our 
efforts in development of and promising approach to achieve lag time of 
8 h considering the bioavailability of the molecule.  
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